Chinese biotech firm WuXi AppTec to invest over $30m in CANbridge

Chinese biotech firm WuXi AppTec to invest over $30m in CANbridge

Photo: WuXi AppTec.

18 February, 2020

CANbridge Pharmaceuticals orphan disease Wuxi AppTec

Printed by Unregistered user on Tue, 22 Jul 2025 08:22:10 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

China's WuXi AppTec acquires US clinical service company Pharmapace

Venture Capital

China: CANBridge $25m Series B; VoxelCloud $10m Series A; Huajiao Live Video $14m funding

Read more from Greater China

Venture Capital

Startup funding in Greater China grows 13% in Q2 on Ximalaya’s $2.4b deal

Cannot rely solely on valuation metrics for AI investments: Cathay Innovation